Abbott Laboratories (ABT) presents a compelling buying opportunity for investors focused on high-quality dividend stocks, especially as its shares have dipped 30% over the past year. The healthcare giant has faced challenges, particularly in its nutrition and diagnostics segments, with first-quarter comparable sales growth of only 3.7%. However, the recent $21 billion acquisition of Exact Sciences introduces promising products, including innovative cancer diagnostic tests, which could enhance Abbott’s growth trajectory.
Despite sluggish top-line growth, Abbott’s FreeStyle Libre continuous glucose monitoring devices continue to drive revenue, and the company is expanding its offerings with new over-the-counter products. With a forward dividend yield of 2.8%, significantly higher than the S&P 500 average, Abbott’s status as a Dividend King makes it an attractive option for income-focused investors amid market volatility.
Investors looking for a solid long-term play may find Abbott Laboratories’ current stock price an opportune entry point, especially when reinvesting dividends for potential superior returns.
Source: fool.com